---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-221626"
form_type: "8-K"
ticker: "ACRV"
cik: "0001781174"
company_name: "Acrivon Therapeutics, Inc."
filed_at: "2026-05-13T20:10:18+00:00"
generated_at: "2026-05-13T22:06:26.562137+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Acrivon Q1 net loss $19.0M; cash $97.7M; key ACR-368 interim readout in H2 2026

## Summary
- Net loss $19.0M vs $19.7M YoY; R&D $15.2M, G&A $4.7M.
- Cash & equivalents $97.7M at March 31, 2026; plus $7.3M from equity financing, runway into Q3 2027.
- ACR-368 Phase 2b registrational study: prespecified interim analysis of serous EC arms planned in H2 2026.
- ACR-2316 Phase 1/2 shows tolerability and durable activity in AP3-prioritized lung cancers; expansion phase ongoing.
- CDK11 inhibitor program (ACR-6840) IND submission targeted for H1 2027.

## SEC filing metadata
- accession: 0001193125-26-221626
- form_type: 8-K
- ticker: ACRV
- cik: 0001781174
- company_name: Acrivon Therapeutics, Inc.
- filed_at: 2026-05-13T20:10:18+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1781174/000119312526221626/0001193125-26-221626-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1781174/000119312526221626/acrv-20260513.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-221626
- JSON: https://secwatch.observer/filing/0001193125-26-221626.json
- Plain text: https://secwatch.observer/filing/0001193125-26-221626.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.